What Is BPC-157?
BPC-157 (Body Protection Compound 157) is a synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Composed of 15 amino acids with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, BPC-157 has emerged as one of the most extensively studied peptides in regenerative research due to its remarkable effects on tissue healing, angiogenesis, and gastrointestinal protection.
Unlike many research peptides that target specific receptor pathways, BPC-157 appears to work through multiple mechanisms — promoting angiogenic repair, modulating growth factor expression, and stabilizing gastrointestinal mucosa. This polyvalent activity profile has made it a cornerstone of peptide research across gastroenterology, orthopedics, and wound healing disciplines.
Amino Acid Structure
BPC-157 is a linear pentadecapeptide (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val; molecular weight about 1419.5 g/mol). Its proline-rich N-terminal segment contributes to the stability that researchers have noted in acidic, gastric-like conditions.
Mechanisms of Action
BPC-157 research has identified several interconnected mechanisms described in preclinical models:
Angiogenesis and Vascular Repair
BPC-157 significantly upregulates vascular endothelial growth factor (VEGF) and promotes the formation of new blood vessels at injury sites. This angiogenic effect accelerates nutrient delivery and waste removal, creating optimal conditions for tissue regeneration. Research has demonstrated increased capillary density in tendon, muscle, and ligament injuries following BPC-157 administration.
Growth Factor Modulation
The peptide upregulates early growth response factor-1 (EGR-1), which triggers a cascade of downstream healing pathways including collagen synthesis, fibroblast proliferation, and extracellular matrix remodeling. This positions BPC-157 upstream of multiple healing processes rather than targeting a single pathway.
Gastrointestinal Cytoprotection
BPC-157 maintains gastrointestinal mucosal integrity through interaction with the nitric oxide (NO) system and prostaglandin pathways. Studies have demonstrated its ability to counteract NSAID-induced gastric lesions and promote ulcer healing — effects that appear independent of gastric acid suppression.
Nitric Oxide System Interaction
The peptide's protective effects involve the NO pathway, particularly in endothelial function and vascular tone regulation. BPC-157 counteracts the deleterious effects of NO-synthase blockade, maintaining critical blood flow to healing tissues.
Key Research Findings
Tendon and Ligament Healing
Multiple preclinical studies have examined BPC-157 in tendon-to-bone healing and ligament repair models. In animal models, BPC-157-treated subjects showed significantly improved biomechanical properties, increased fibroblast density, and faster functional recovery compared to controls. The peptide appears to enhance type I collagen production — the primary structural protein in tendons and ligaments — while simultaneously reducing inflammatory markers at the injury site.
Muscle Regeneration
Research on muscle crush injuries and transections has shown BPC-157 accelerates myofiber regeneration and reduces fibrosis. The peptide promotes satellite cell activation and fusion, key processes in skeletal muscle repair. Functional recovery metrics, including muscle force generation, showed significant improvement in treated groups.
Bone Healing
BPC-157 has demonstrated osteogenic effects in fracture models, accelerating callus formation and improving bone density at fracture sites. The peptide appears to enhance osteoblast activity while modulating osteoclast function, potentially tilting the balance toward net bone formation rather than resorption.
Gastrointestinal Protection
Originally isolated from gastric juice, BPC-157's gastrointestinal effects are among its most well-documented. The peptide has been studied in models of NSAID-induced gastric lesions, ethanol-induced stomach damage, and inflammatory bowel disease. Its cytoprotective effects extend throughout the entire gastrointestinal tract, including esophageal, gastric, duodenal, and colonic protection.
Neurological Applications
Emerging research suggests BPC-157 may offer neuroprotective benefits. Studies have explored its effects on traumatic brain injury models, spinal cord injury recovery, and peripheral nerve regeneration. The peptide appears to counteract dopamine and serotonin disruptions in certain experimental models, opening avenues for neuropsychiatric research.
Key Research References
- Tewari K, et al. Peptide Supplements and Their Therapeutic Applications in Sports Medicine. Am J Sports Med. 2026. PMID: 42578445
- Arunim, et al. Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel. 3 Biotech. 2026;16(8):312. PMID: 42555375
- Biçer O, et al. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Jt Dis Relat Surg. 2026;37(3):822-837. PMID: 42542926
- Mendias CL, et al. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026;56(8):1921-1935. PMID: 41966639
- Yuan C, et al. From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. Int J Mol Sci. 2026;27(6). PMID: 41898733
- Rahman OF, et al. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. J Am Acad Orthop Surg Glob Res Rev. 2026;10(1). PMID: 41490200
Study Designs in the Published Literature
Published BPC-157 studies are preclinical (cell-culture and animal models). Routes, amounts and study durations vary by model and are reported in the cited papers; researchers should consult the primary literature. BioSim does not provide dosing, administration or treatment guidance. BPC-157 is sold strictly for laboratory research, has not been evaluated by the FDA, and is not for human consumption.
BPC-157 is sold strictly for laboratory research purposes and has not been evaluated by the FDA for human use.
Safety Profile
Published toxicology data are limited to preclinical models; see the cited literature.
Comparison: BPC-157 vs TB-500
BPC-157 and TB-500 (Thymosin Beta-4 fragment) are frequently studied together due to complementary healing mechanisms:
- BPC-157: Promotes angiogenesis, upregulates growth factor expression, enhances collagen synthesis, provides gastrointestinal protection. Broader systemic effects.
- TB-500: Primary mechanism is actin polymerization and cell migration. More targeted to cellular motility and wound closure.
- Combined use: The two peptides act through different mechanisms and are often studied side by side; see our BPC-157 vs TB-500 comparison.
Storage and Handling
For optimal stability in laboratory settings:
- Lyophilized (dry powder): Store at -20°C, protected from light. Stable for 12-24 months under proper storage conditions.
- Reconstituted: Use bacteriostatic water (0.9% benzyl alcohol) for reconstitution. Store at 2-8°C for up to 4 weeks. Avoid repeated freeze-thaw cycles.
- Light sensitivity: BPC-157 is moderately light-sensitive. Store vials in light-protective containers or amber vials.
- pH stability: The peptide is most stable at pH 6-7. Avoid exposure to strongly acidic or basic solutions.
Frequently Asked Questions
What is the molecular weight of BPC-157?
BPC-157 has a molecular weight of 1419.5 g/mol. It's a pentadecapeptide composed of 15 amino acids, making it one of the smaller research peptides commonly studied.
Is BPC-157 orally bioavailable?
Published preclinical studies have used several routes of administration in animal models; see the cited papers. BioSim provides no administration guidance.
Can BPC-157 cross the blood-brain barrier?
Research suggests BPC-157 does cross the blood-brain barrier, which enables its documented neuroprotective effects in CNS injury and neurodegenerative disease models. This property distinguishes it from many peptides that remain peripherally active.
How is BPC-157 different from BPC-157 Arg salt vs Acetate?
BPC-157 Acetate is the standard form used in most published research — the peptide is synthesized as an acetate salt for improved stability. BPC-157 Arginine salt is a variant with arginine as the counter-ion, which some researchers prefer for specific solubility characteristics. Both forms contain the identical peptide sequence; the difference is the salt form and dissolution profile.
Does BioSim provide dosage guidance for BPC-157?
BPC-157 is sold strictly for laboratory research and in-vitro studies. No. BioSim does not provide dosage, administration or treatment guidance. Published preclinical study designs are described in the papers referenced above. This product is not for human consumption and has not been evaluated by the FDA for any medical indication.
Related Research Compounds
Related reading: BPC-157 vs TB-500 | GHK-Cu vs BPC-157 | Tissue Repair Research category
Disclaimer: BPC-157 is a research peptide sold for in-vitro and laboratory research purposes only. The information provided here is a summary of published preclinical research and does not constitute medical advice. This product has not been evaluated by the FDA and is not intended for human consumption, diagnosis, treatment, or prevention of any disease.
Research These Compounds: High-purity research peptides available from BioSim: BPC-157, TB-500. All 99%+ purity by HPLC; available certificates are published on our COA page.
Research This Compound: BPC-157 research peptide available from BioSim Peptides — 99%+ purity by HPLC, lyophilized; available certificates are published on our COA page.
